Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort
NCT05004727Phase 4Recruiting
- Sponsor
- NYU Langone Health
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of guselkumab in psoriasis, psoriatic arthritis (PsA), sponsored by NYU Langone Health. Started Feb 2022; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05004727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004727.